Arkadiusz Dudek, M.D., Ph.D.

Dr Dudek is an Associate Professor of Medicine and Director of the Clinical Trials Office in the Hematology, Oncology and Transplantation (HOT) Division.

Dr. Dudek received his M.D. in 1989 from the Medical Academy, University of Warsaw, Poland. He received internal medicine residency training in Harrisburg, Pennsylvania and subspecialty training in Hematology, Oncology and Transplantation at the University of Minnesota. He received his Ph.D. from Military Medical Academy of Warsaw in 1998. He then joined the Faculty in 1997.

Dr. Dudek's clinical interest is focused on the management of thoracic malignancies, but includes the treatment of malignant hematologic disorders, malignant melanoma, kidney cancer and blood and marrow transplantation. His clinical research interests includes phase I and II clinical trials in solid tumors. His laboratory research is focused on cancer angiogenesis.

Selected Publications

Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A.  Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: Novel mechanisms for modulation of hematopoiesis.  Blood 2003; 101:4687-4694.

Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ.  Bronchiolitis obliterans in chronic graft-versus-host disease: Analysis of risk factors and treatment outcomes.  Biol Blood Marrow Transplant 2003; 9:657-666.

Dudek AZ, Lesniewski-Kmak K, Bliss RL, Brunstein C, Condon DL, Kratzke RA. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer. Lung. 2005; 183:43-52.

Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer. 2006; 51:89-96. 

Arodz T, Yuen DA, Dudek AZ. Ensemble of linear models for predicting drug properties.  J Chem Inf Model. 2006; 46:416-23. 

Dudek AZ, Mahaseth H. Hematopoietic stem cell transplant-related airflow obstruction. Curr Opin Oncol. 2006; 18:115-9.

Dudek AZ, Arodz T, Galvez J.  Computational methods in developing quantitative structure-activity relationships (QSAR): a review. Comb Chem High Throughput Screen. 2006; 9:213-28.

Jasinski P, Zwolak P, Terai K, Dudek AZ. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo.  Trans Res. DOI: 10.1016/j.trsl.2008.09.001.

Zwolak P, Jasinski P, Terai K, Gallus NJ, Ericson ME, Clohisy DR, Dudek AZ. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur J Cancer. 2008; 44:2506-2517.

Jasinski P, Terai K, Zwolak P, Dudek AZ. Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C.  Eur J Cancer. 2008; 44:1315-1322.

Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.  Am J Clin Oncol. 2008; 31:173-181.

Dudek AZ, Chereddy S, Nguyen S, Wagner JE, Maddaus M.  Neoadjuvant chemotherapy with reduced-dose carboplatin and gemcitabine for non-small cell lung cancer in a patient with Fanconi anemia.  J Thorac Oncol. 2008; 3:447-450.

Dudek AZ, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK.. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol. 2008; 3:394-399.

Nguyen S, Franklin M, Dudek AZ. Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinib. Transl Res. 2008; 151:194-196.

Mulamalla K, Truskinovsky AM, Dudek AZ. Rare case of hemangiopericytoma responds to sunitinib. Transl Res. 2008; 151:129-133.